NASDAQ: EFTREffector Therapeutics Inc Stock
$1.81-0.04 (-2.16%)
Updated Apr 25, 2024
EFTR Price
$1.81
Fair Value Price
N/A
Market Cap
$6.67M
52 Week Low
$1.60
52 Week High
$37.00
P/E
-0.11x
P/B
-1.15x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$35.81M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-4.55
Operating Cash Flow
-$30M
Beta
1.01
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
EFTR Overview
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cancer treatments. Its lead product candidates are Tomivosertib and Zotatifin. It has a collaboration agreement with Pfizer Inc. eFFECTOR Therapeutics was founded in 2012 and is headquartered in Solana Beach, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EFTR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EFTR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EFTR is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
EFTR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more EFTR due diligence checks available for Premium users.
Be the first to know about important EFTR news, forecast changes, insider trades & much more!
EFTR News
Valuation
EFTR fair value
Fair Value of EFTR stock based on Discounted Cash Flow (DCF)
Price
$1.81
Fair Value
-$2.09
Undervalued by
186.62%
EFTR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EFTR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
15.41x
Market
40.97x
EFTR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.15x
Industry
5.8x
EFTR's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.1M
Profit Margin
0%
EFTR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$20.5M
Liabilities
$26.3M
Debt to equity
-4.55
EFTR's short-term liabilities ($25.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EFTR's short-term assets ($19.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EFTR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EFTR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.6M
Investing
$8.9M
Financing
$6.1M
EFTR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EFTR vs Biotech Stocks
Effector Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.